• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by scPharmaceuticals Inc.

    4/28/25 4:01:03 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCPH alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    scPharmaceuticals Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    810648105

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    810648105


    1Names of Reporting Persons

    Luther King Capital Management Corporation
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,121,170.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,121,170.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,121,170.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.2 %
    12Type of Reporting Person (See Instructions)

    IA, CO


    SCHEDULE 13G

    CUSIP No.
    810648105


    1Names of Reporting Persons

    J. Luther King, Jr.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,249,170.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,249,170.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,249,170.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.5 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    scPharmaceuticals Inc.
    (b)Address of issuer's principal executive offices:

    25 Mall Road, Suite 203, Burlington, Massachusetts 01803
    Item 2. 
    (a)Name of person filing:

    Luther King Capital Management Corporation J. Luther King, Jr.
    (b)Address or principal business office or, if none, residence:

    301 Commerce Street, Suite 1600, Fort Worth, Texas 76102
    (c)Citizenship:

    Luther King Capital Management Corporation - Delaware / J. Luther King, Jr. - USA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    810648105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Luther King Capital Management Corporation - 3,121,170 J. Luther King, Jr. - 3,249,170
    (b)Percent of class:

    Luther King Capital Management Corporation - 6.2% J. Luther King, Jr. - 6.5
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Luther King Capital Management Corporation - 3,121,170 J. Luther King, Jr. - 3,249,170

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    Luther King Capital Management Corporation - 3,121,170 J. Luther King, Jr. - 3,249,170

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Luther King Capital Management Corporation
     
    Signature:/s/ J. Luther King, Jr.
    Name/Title:J. Luther King, Jr., President
    Date:04/28/2025
     
    J. Luther King, Jr.
     
    Signature:/s/ J. Luther King, Jr.
    Name/Title:J. Luther King, Jr.
    Date:04/28/2025
    Get the next $SCPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCPH

    DatePrice TargetRatingAnalyst
    9/7/2023$20.00Buy
    Craig Hallum
    12/1/2022$25.00Outperform
    Cowen
    10/21/2022$14.00Buy
    Jefferies
    10/11/2022$11.00Mkt Perform → Outperform
    SVB Leerink
    8/2/2022$10.00Buy
    Maxim Group
    9/9/2021$6.00Market Perform
    SVB Leerink
    More analyst ratings

    $SCPH
    Financials

    Live finance-specific insights

    See more
    • scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

      BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, May 14, 2025, to discuss the financial results for the first quarter 2025 and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under "News & Events" in the Investor Relations section of the Company's website,

      5/7/25 4:01:44 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th, at 4:30pm ET BURLINGTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat

      3/19/25 4:01:00 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025

      BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 19, 2025, to discuss the financial results for the fourth quarter and full year 2024, and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under "News & Events" in the Investor Relations section of the

      3/12/25 4:01:00 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

      BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, May 14, 2025, to discuss the financial results for the first quarter 2025 and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under "News & Events" in the Investor Relations section of the Company's website,

      5/7/25 4:01:44 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences

      BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will participate in the following upcoming investor conferences: The Citizens Life Sciences Conference: Presentation on Wednesday, May 7 at 9:30 a.m. ET.Craig-Hallum 22nd Annual Institutional Investor Conference: Wednesday, May 28, Investor Meetings OnlyH.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ: Presentation on May 20 at 10:00 a.m. ET. A webcast of the presentations

      5/1/25 4:01:00 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th, at 4:30pm ET BURLINGTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat

      3/19/25 4:01:00 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Tucker John H gave a grant of 200,000 shares, decreasing direct ownership by 31% to 440,847 units (SEC Form 4)

      4 - scPharmaceuticals Inc. (0001604950) (Issuer)

      2/12/25 4:32:59 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and Treasurer Nokes Rachael was granted 88,445 shares, increasing direct ownership by 131% to 156,061 units (SEC Form 4)

      4 - scPharmaceuticals Inc. (0001604950) (Issuer)

      2/12/25 4:27:03 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and Treasurer Nokes Rachael covered exercise/tax liability with 5,235 shares, decreasing direct ownership by 7% to 67,616 units (SEC Form 4)

      4 - scPharmaceuticals Inc. (0001604950) (Issuer)

      1/7/25 4:30:06 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for FUROSCIX issued to SCPHARMACEUTICALS INC

      Submission status for SCPHARMACEUTICALS INC's drug FUROSCIX (ORIG-1) with active ingredient FUROSEMIDE has changed to 'Approval' on 10/07/2022. Application Category: NDA, Application Number: 209988, Application Classification: Type 3 - New Dosage Form

      10/11/22 1:54:57 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on scPharmaceuticals with a new price target

      Craig Hallum initiated coverage of scPharmaceuticals with a rating of Buy and set a new price target of $20.00

      9/7/23 9:06:27 AM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen initiated coverage on scPharmaceuticals with a new price target

      Cowen initiated coverage of scPharmaceuticals with a rating of Outperform and set a new price target of $25.00

      12/1/22 7:54:00 AM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on scPharmaceuticals with a new price target

      Jefferies resumed coverage of scPharmaceuticals with a rating of Buy and set a new price target of $14.00

      10/21/22 7:40:23 AM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

      NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an

      3/1/22 4:05:00 PM ET
      $APYX
      $LNTH
      $PRTK
      $SCPH
      Medical/Dental Instruments
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Biotechnology: Pharmaceutical Preparations

    $SCPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Orbimed Advisors Llc bought $2,000,000 worth of shares (500,000 units at $4.00) (SEC Form 4)

      4 - scPharmaceuticals Inc. (0001604950) (Issuer)

      8/15/24 4:51:14 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by scPharmaceuticals Inc.

      SCHEDULE 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

      4/28/25 4:01:03 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by scPharmaceuticals Inc.

      DEFA14A - scPharmaceuticals Inc. (0001604950) (Filer)

      4/21/25 4:12:38 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by scPharmaceuticals Inc.

      DEF 14A - scPharmaceuticals Inc. (0001604950) (Filer)

      4/21/25 4:10:57 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

      SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

      11/15/24 4:06:50 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

      SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

      11/14/24 5:48:35 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

      SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

      11/14/24 3:58:44 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care